NCT03449108View on ClinicalTrials.gov

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 27, 2018

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions
Bone SarcomaDedifferentiated ChondrosarcomaGiant Cell Tumor of BoneMalignancy in Giant Cell Tumor of BoneMalignant Solid NeoplasmOvarian CarcinosarcomaPlatinum-Resistant Ovarian CarcinomaPoorly Differentiated Thyroid Gland CarcinomaRecurrent OsteosarcomaRecurrent Ovarian CarcinomaRefractory OsteosarcomaSoft Tissue SarcomaThyroid Gland Anaplastic CarcinomaThyroid Gland Squamous Cell CarcinomaUndifferentiated High Grade Pleomorphic Sarcoma of BoneTriple Negative Breast Cancer
Interventions
BIOLOGICAL

Aldesleukin

Given IV

BIOLOGICAL

Autologous Tumor Infiltrating Lymphocytes LN-145

Given IV

BIOLOGICAL

Autologous Tumor Infiltrating Lymphocytes LN-145-S1

Given IV

DRUG

Cyclophosphamide

Given IV

DRUG

Fludarabine

Given IV

BIOLOGICAL

Ipilimumab

Given IV

BIOLOGICAL

Nivolumab

Given IV

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
collaborator

Iovance Biotherapeutics, Inc.

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER